Sio Gene Therapies Inc.

OTCPK:SIOX Stock Report

Market Cap: US$34.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Sio Gene Therapies Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

David Nassif

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.6yrs
CEO ownership0.06%
Management average tenureno data
Board average tenureno data

Recent management updates

Analysis Article • Mar 04

Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysis Article • Nov 19

Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

Recent updates

Analysis Article • Oct 19

Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jun 27

Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Dec 27

My Favorite Stock For 2022: Sio Gene Therapies

SIOX made stellar progress in 2021. Moreover, it is resuming an important gene therapy program in Parkinson's disease. Yet the market is essentially assigning the company's programs and FDA drug designations zero value. I believe this sets up a very favorable risk/reward situation, and I've weighted SIOX in my portfolio accordingly.
Seeking Alpha • Oct 25

Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure

SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company. Investors seem to have latched on the latter news rather than the former which I think is short-sighted. I'm a buyer here with the company having plenty of cash, a miniscule EV and very promising clinical results.
Analysis Article • Sep 28

We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 07

We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 04

Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analysis Article • Jan 28

What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?

A look at the shareholders of Sio Gene Therapies, Inc. ( NASDAQ:SIOX ) can tell us which group is most powerful. Large...
Analysis Article • Dec 24

Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 19

Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

CEO Compensation Analysis

How has David Nassif's remuneration changed compared to Sio Gene Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$29m

Sep 30 2022n/an/a

-US$50m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022US$2mUS$454k

-US$72m

Dec 31 2021n/an/a

-US$62m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021US$1mUS$414k

-US$32m

Dec 31 2020n/an/a

-US$46m

Sep 30 2020n/an/a

-US$49m

Jun 30 2020n/an/a

-US$53m

Mar 31 2020US$2mUS$300k

-US$73m

Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Nassif (69 yo)

4.6yrs
Tenure
US$1,617,173
Compensation

Mr. David W. Nassif, J.D., serves as Chief Executive Officer of Sio Gene Therapies Inc. since May 2022 and also serves as its General Counsel since July 01, 2019 and serves as its Chief Financial Officer....

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/07 14:02
End of Day Share Price 2024/02/07 00:00
Earnings2022/12/31
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sio Gene Therapies Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Yun ZhongBTIG
Jason ButlerCitizens JMP Securities, LLC